Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET).
James C. Yao
Consultant or Advisory Role - Endo Pharmaceuticals; Ipsen; Novartis; Pfizer
Honoraria - Novartis
Research Funding - Genentech; Novartis
John D. Hainsworth
No relevant relationships to disclose
Edward M. Wolin
Consultant or Advisory Role - Novartis
Marianne E. Pavel
Consultant or Advisory Role - Novartis
Eric Baudin
Honoraria - Novartis
David Gross
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Philippe Ruszniewski
Consultant or Advisory Role - Ipsen; Novartis; Pfizer
Honoraria - Ipsen; Novartis; Pfizer
Research Funding - Ipsen; Novartis; Pfizer
Paola Tomassetti
No relevant relationships to disclose
Ashok Panneerselvam
Employment or Leadership Position - Novartis
Stephen Saletan
Employment or Leadership Position - Novartis
Judith Klimovsky
Employment or Leadership Position - Novartis
Stock Ownership - Novartis